2016 sales: $931 million
Sales of hypertension med Bystolic are headed south, and Allergan can’t do all that much to stop them—at least where price is concerned.
Last September, the drugmaker pledged to limit price increases to below 10% as part of a “social contract” with patients, and it stuck to its word in January, announcing it would take Bystolic’s price up by 9%.
The drug, which Allergan expects to see fall victim to generic competition in the not-too-distant future, was at one time shared by Forest Labs and Johnson & Johnson. But in April 2012, Forest inked a pact to keep Bystolic revenues all to itself, and in 2014, famed activist investor Carl Icahn helped engineer a sale of Forest to Allergan.
Since then, Bystolic—along with products such as GI treatments Linzess and Viberzi—have benefited from Allergan’s “ability to do both specialty and primary care,” CEO Brent Saunders said on Allergan’s first-quarter earnings call in May. “Why we can do volume over price is in large part because volume is in primary care; … being able to participate in both parts of that market is strategically critical to our business model.”
When Bystolic copies do arrive in the U.S., nearly all the med’s revenue will be at stake. Of the $640.5 million it generated in 2016 for Allergan, $638.8 million came from the U.S. Evaluate Pharma, for one, predicts the med will rack up just $214 million in 2022, or $591 million if other versions marketed by Menarini are counted.